TPMT Genotype and Adverse Effects of Azathioprine among Jordanian Group

Curr Drug Metab. 2019;20(11):889-897. doi: 10.2174/1389200220666191021100953.

Abstract

Background: Inflammatory Bowel Disease (IBD) is a common disease affecting many patients. This disease is treated by azathioprine and TPMT genetic polymorphism affecting the patient's tolerance. The aim of this study is to investigate the importance of TMPT genotyping in reducing the incidence of adverse effects of azathioprine.

Methods: One hundred and forty-one IBD patients were followed for azathioprine Adverse Drug Reaction (ADR). Patients were genotyped for TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C.

Results: The frequency of Azathioprine adverse effect was about 35.5%. An association between TPMT genotypes 1/3A and 3B/3B and azathioprine related bone marrow suppression was found (P value ≤ 0.05).

Conclusion: The findings suggest that there was a significant association between TPMT genotypes 1/3A and 3B/3B and azathioprine related bone marrow suppression.

Keywords: Azathioprine; TPMT genotype; adverse effects; chronic granulmatous inflammation; gastrointestinal tract; inflammatory bowel disease (IBD)..

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Azathioprine / adverse effects*
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / epidemiology
  • Jordan / epidemiology
  • Methyltransferases / genetics*
  • Middle Aged
  • Polymorphism, Genetic
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Methyltransferases
  • TPMT protein, human
  • Azathioprine